OncoMatch/Clinical Trials/NCT05168618
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Is NCT05168618 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Atezolizumab and Cabozantinib S-malate for castration-resistant prostate carcinoma.
Treatment: Atezolizumab · Cabozantinib S-malate — This phase II trial tests whether cabozantinib and atezolizumab work to shrink tumors in patients with castrate-resistant prostate cancer that had spread to other places in the body (metastatic). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib and atezolizumab may kill more tumor cells in patients with metastatic castrate-resistant prostate cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Required: Stage IV, IVA, IVB
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: androgen deprivation therapy — hormone sensitive state
Metastatic disease progression after continuous androgen deprivation therapy for hormone sensitive state
Must have received: novel hormonal therapy (abiraterone acetate, enzalutamide, apalutamide, darolutamide)
Disease progression on or after at least one prior novel hormonal therapy (NHT) (defined as second-generation antiandrogen therapies that include but are not limited to abiraterone acetate, enzalutamide, apalutamide, darolutamide)
Cannot have received: chemotherapy
Exception: taxane-based in metastatic castration-sensitive disease is allowed
Prior chemotherapy in the metastatic castration refractory prostate cancer setting is not allowed (taxane-based in metastatic castration-sensitive disease is allowed)
Cannot have received: cabozantinib (cabozantinib)
Prior treatment with cabozantinib
Cannot have received: immune checkpoint inhibitor
Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-a, anti-PD1 and anti-PD-L1 therapeutic antibodies
Cannot have received: systemic immunostimulatory agent (interferon, interleukin 2)
Prior treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin 2 [IL-2]) within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment
Cannot have received: small molecule kinase inhibitor
Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment
Cannot have received: cytotoxic, biologic or other systemic anticancer therapy
Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) within 4 weeks before first dose of study treatment
Cannot have received: investigational agent
Receiving other investigational agents
Lab requirements
Blood counts
ANC >= 1500/mm^3 without G-CSF support; WBC >= 2500/uL; lymphocyte count >= 0.5 x 10^9/L (500/uL); platelet count >= 100,000/mm^3 without transfusion in prior 2 weeks; hemoglobin >= 9 g/dL
Kidney function
Serum creatinine <= 1.5 x ULN or calculated creatinine clearance >= 40 mL/min by Cockcroft-Gault formula; Urine protein/creatinine ratio <= 1mg/mg or 24-hour urine protein <= 1 g
Liver function
Total bilirubin <= 1.5 x ULN (Gilbert's <= 3 x ULN); AST and ALT <= 2.5 x ULN (<= 5 x ULN with liver metastases); ALP <= 3 x ULN (<= 5 x ULN with liver or bone metastases); serum albumin >= 2.5 g/dl
Cardiac function
QTcF <= 500 ms per ECG; no NYHA class II-IV CHF, unstable angina, serious unstable arrhythmias, recent stroke/MI/thromboembolic event within 6 months, uncontrolled hypertension
See inclusion and exclusion criteria for full details on organ function requirements
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Huntsman Cancer Institute/University of Utah · Salt Lake City, Utah
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify